Patrick Campbell

Details of an analysis from ADA 2024 compared matched cohorts from SURMOUNT-1 and SURMOUNT-2 to determine drivers of differences in weight loss from the trials.

Omnipod 5 improved HbA1c from 8.2% to 7.4% in 13 weeks among adults with type 2 diabetes in the SECURE-T2D trial, with a nearly 5-hour increase in time in range per day.

ADA study highlights disparities in CGM access for children with type 1 diabetes, showing delays for publicly insured and minority children.

New data from INHALE-3 at ADA 84th Scientific Sessions show inhaled insulin (Afrezza) is safe, effective for type 1 diabetes, improving glycemic control and HbA1c goals.

Atul Malhotra, MD, discusses the results of the SURMOUNT-OSA trial and how they inform clinicians on the role of tirzepatide in OSA and obesity.

An analysis of patients with acute coronary syndrome shows women receive less lipid-lowering therapy and are less likely to meet LDL-C targets than men.

Zerlasiran, a siRNA agent, significantly reduced lipoprotein(a) levels by approximately 90% at 48 weeks in high-risk cardiovascular patients, per phase 2 data from Silence Therapeutics.

EULAR 2024 data link maternal intake of over 252 grams of fish per week with higher risk of juvenile idiopathic arthritis in offspring, but causation is unclear.

A study from EULAR details the ability of the FIRST self-questionnaire to identify fibromyalgia in patients with rheumatoid arthritis.

New research from the SOLOST-WHF trial suggests sotagliflozin is a cost-effective treatment for diabetes patients with recent heart failure, with high cost-effectiveness probability.

Data from a new study details the apparent benefit of adding polygenic risk scores to improve cardiovascular risk stratification.

Analysis of NHANES data from 1999 to 2020 provides some evidence of diet quality improvement but highlights low rates of adults achieving ideal diet quality.

An analysis of real-world data from propensity score-matched pairs of breast cancer patients treated with anthracyclines suggests statin use was associated with an 18% reduction in all-cause mortality.

A review of nearly 500 studies spanning more than 30 years details associations between weather events and cardiovascular risk.

An analysis of the REALISTIC trial from EULAR 2024 details the effects of certolizumab pegol in rheumatoid arthritis based on rheumatoid factor levels and prior TNF inhibitor use.

New research reveals that elevated lipoprotein(a) and oxidized phospholipids are independent risk factors for early-stage heart failure progression.

A propensity score matched analysis suggests use of SGLT2 inhibitors could reduce risk of negative outcomes in patients with systemic lupus erythematosus and type 2 diabetes.

An analysis of survey data from more than 200 patients with atopic dermatitis details treatment satisfaction and provider trust based on racial/ethnic backgrounds of patients.

A new study suggests the AHA's PREVENT risk calculator may reduce statin use for primary prevention, affecting eligibility for millions of adults.

A post-hoc analysis of the ARCADIA program provides insight into the speed of itch relief onset observed with nemolizumab among patients with moderate-to-severe atopic dermatitis.

An analysis of CDC WONDER data details disparities among the cardiovascular mortality rate for patients with rheumatoid arthritis in the US.

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

Study from RAD 2024 finds 36% higher risk of nonmelanoma skin cancer in patients with atopic dermatitis relative to matched controls.

An analysis of data from the LIBERTY AD trial presented at RAD 2024 details the risk of infections observed with dupilumab use with up to 5 years of follow-up.

An analysis of data from the NIH's All of Us program details the prevalence of fatigue among patients with pruritus among US patients.

A real-world analysis of 60 patients suggests traolkinumab was effective in atopic dermatitis, regardless of prior therapy use.

At Heart in Diabetes, full results of the GRACE trial detailed the benefits of relacorilant use from both parts of the 2-part, phase 3 trial.

Kaitlin Mayne, MBChB, discusses an analysis of the EMPA-Kidney trial examining the effects of multimorbidity, polypharmacy, and quality of life on effects of empagliflozin.

A study found that only 0.32% of 1.2 million patients underwent Lp(a) testing, with non-Hispanic Black and Hispanic patients significantly less likely to receive the test compared to White patients.